Industry news that matters to you.  Learn more

Archives for September 2011

FyMed Expands Its Drug Discovery and Development Portfolio Through Innovative Personalized Medicine Strategies

FyMed, Inc., a biopharmaceutical company focused on innovative drug development through sophisticated biomarker discovery methodologies in personalized medicine, today announced strategic and operational expansion plans following the successful completion of major preclinical drug studies utilizing the Company’s proprietary companion diagnostic and prognostic technologies.

NanoInk Platform Proven to Reproducibly Detect Protein Biomarkers From Dried Blood Spot Samples

The Nano BioDiscovery Division of NanoInk, Inc. provides a new generation of array-based instrument systems, assay kits, and contract services for nanoscale protein studies. Based on patented Dip Pen Nanolithography (DPN) technology, tests run on NanoInk’s NanoArray Assay System consume much smaller sample volumes than do traditional ELISA and bead-based assays, generating more data with less starting material and minimizing the amount of patient blood needed for analysis.

SignatureMD and Biophysical Corp. Announce Partnership To Bring Pre-Diabetes Program To Doctors Nationwide

SignatureMD, a leading provider of personalized or concierge medicine, and Biophysical Corporation, dedicated to advancing clinical knowledge and quality of life for its clients, announced today a joint program to bring an advanced pre-diabetes biomarker test to SignatureMD’s affiliated medical practices nationwide.

EBI Shutting Down the International Protein Index

According to a story today on Genome Web’s BioInform, the European Bioinformatics Institute (EBI) will be shutting down the International Protein Index at the end of this month. Although previous releases will continue to be available, the IPI website will no longer be maintained.

Definiens to Introduce New Generation of Products for Tissue-based Biomarker Research at the International Definiens Symposium

Definiens, the leading Health Image Intelligence company, announces that it will release a new generation of products at the International Definiens Symposium at the Moffitt Cancer Center in Tampa, FL on October 17–18. The annual symposium is the premier forum for Definiens users and developers from around the world to present the latest applications, research and workflows in life science image and data analysis. One focus of this year’s symposium will be tissue-based biomarker research and image analysis in clinical trials. The high-caliber program will include a speaker panel with key opinion leaders from industry and academia.